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INTRODUCTION 
In December 2019, a severe respiratory disease appeared 
in China, which is now named coronavirus disease 2019 
(COVID-19) (World Health Organization, 2020a). The 
World Health Organization has declared the COVID-19 
outbreak a pandemic. This disease has spread to 215 
countries, infecting more than six million people and 
causing more than 370 thousand deaths as of May 31st, 
2020 (Worldometer, 2020). COVID-19 is a disease caused 
by Severe Acute Respiratory Syndrome Corona Virus 2 
(SARS-CoV-2) infection with symptoms of cough, fever, 
fatigue, headache, and shortness of breath (Guan et al., 
2020; Wang et al., 2020). 
The diagnosis of COVID -19 is made through observing 
the clinical manifestations that arise and the diagnostic 
examination of SARS-CoV-2. The SARS-CoV-2 
diagnostic tests are carried out through Reverse 
Transcription polymerase chain reaction (RT-PCR) 
testing as a method to confirm the diagnosis of cases of 
COVID -19 according to WHO guidelines (World Health 
Organization, 2020b). In this paper, we discuss the 
biology of SARS-CoV-2 and the principles of RT-PCR as 
the basis to understand the method of detection of SARS-
CoV-2 and problems that may occur using this detection 
method. 
 
SARS-CoV-2 BIOLOGY 
The SARS-Cov-2, an agent causing a disease called 
COVID-19 is a new species of coronaviruses. The disease 
was first reported in Wuhan, China in 2019 (World 
Health Organization, 2020a). Coronavirus belongs to the 
order of Nidovirales, identified by its envelope 
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characteristics and positive-sense RNA as genetic 
material. The length of the coronavirus genome is about 
26,4–31,7 kb. Coronaviridae and Roniviridae family are 
the largest RNA virus among other viruses (King et al., 
2011). The SARS-CoV-2 genome is 29.9 kb (Forster et al., 
2020). 
As a member of Nidovirales, coronavirus is classified into 
the family of Coronaviridae which usually has three or 
four envelope proteins. Viruses that belong to 
Coronaviridae family have the most abundant 
membrane protein (M) among other proteins, i.e. spike 
glycoprotein (S), nucleocapsid protein (N), an envelope 
protein (E), dan hemagglutinin-esterase protein (HE) as 
visualized in Figure 1 by King et al. (2011). 
 
Figure 1. Envelope structure of coronavirus. The outer layer of 
coronavirus consists of S, HE (only found in Betacoronavirus 
cluster), M, N, and E protein (King et al., 2011) 
 
Coronavirus has a few E proteins on the outer layer of its 
envelope. It is a pentameric integral membrane protein 
that facilitates the movement of molecules passing 
through the ion channel and/or viroporin. Even though 
there is only a small number of this protein, it was 
identified as an essential element of virion 
morphogenesis and a virulent factor of Severe Acute 
Respiratory Syndrome Virus (SARS)-CoV (King et al., 
2011). Wan et al. (2020) reported that SARS-CoV-2 and b 
bat SARS-like coronavirus were in the same b genus. 
Both were also originated from the same ancestral line. 
Human SARS-CoV and bat SARS-CoV can infect a target 
cell through angiotensin-converting enzyme 2 (ACE2) 
receptor. Alignment of Receptor-Binding Domain (RBD) 
of SARS-CoV and SARS-CoV-2 showed that SARS-CoV-
2 RBD had a mutation on 105 residues. It was predicted 
that the mutation can enhance the affinity of SARS-CoV-
2 RBD to the ACE2 receptor (Wan et al., 2020). 
Spike glycoprotein (S) is one of the targets of T cell 
response in the immune system. It acts as an inducer in 
the neutralization of virus infectivity by antibodies (King 
et al., 2011). The S protein also promotes the binding of the 
virus envelope to the ACE2 receptor and the entry of the 
virus into the cell target (Wan et al., 2020). 
Angiotensin-converting enzyme 2 genes are expressed in 
several human cells including endothelial cells of small 
and large arteries and veins, smooth muscle cells, 
enterocytes of the small intestine (duodenum, jejunum, 
and ileum), alveolar epithelial cells,  basal cell layer of the 
epidermis hair follicle, cardiac myofibroblast and fat cell 
membrane in several organs, smooth muscle cells 
surrounding the sebaceous glands in the skin, endothelial 
and smooth muscle cell of the brain, parietal epithelial cell 
of the kidney, and proximal tubular cell of the kidney. 
Epithelial cells of lungs and small intestine contain an 
abundant amount of ACE2 protein. However, ACE2 
protein is not identified in the upper respiratory tract, 
such as an oral cavity, nasal mucosa, and nasopharynx. It 
is also not identified in enterocytes of the stomach and 
colon, endothelial lining of the sinusoids liver, spleen, 
lymph nodes, thymus, immune cells (B cell, T 
lymphocyte, and macrophage), bone marrow, and 
kidney (Hamming et al., 2004). Despite ACE2 proteins are 
scattered all over endothelial and smooth muscle cells, 
not every organ is infected by a coronavirus. SARS-CoV-
2 may need a co-receptor as in found in HIV. The HIV 
requires surface receptor CD4 and chemokine co-
receptor for infecting and entering the cell target (Zhang 
et al., 1996). 
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POLYMERASE CHAIN REACTION 
Polymerase Chain Reaction (PCR) is a DNA 
amplification technique that was invented by Karl Mullis 
in 1984 (Mullis, 1987). This technology is commonly used 
for pathogen identification, forensic analysis (Schaad & 
Frederick, 2002), gene identification, and genetic 
engineering (Garibyan & Avashia, 2013). The principle of 
the PCR process is the alteration of temperature using 
DNA polymerase used in DNA replication in the living 
cells. The temperature is altered to facilitate denaturation 
(separating DNA double-stranded), annealing (primer 
attachment to DNA template), and elongation (DNA 
amplification) process. There are several main 
components required for amplification in the PCR 
process: DNA sample, DNA polymerase enzyme, 
primer, and buffer. The reaction is catalyzed by DNA 
polymerase using a DNA sample as a template (Joshi & 
Deshpande, 2011). 
Primers are short pieces of single-stranded DNA that can 
be designed for restricting the segment of DNA target 
(Schaad & Frederick, 2002). In the process of 
amplification, the sample is used in a small amount. 
Therefore, PCR becomes a sensitive technique for DNA 
identification (Garibyan & Avashia, 2013). 
Molecular biologists have developed variations of the 
original PCR process such as Reverse Transcriptase PCR 
(RT-PCR), Real-time PCR, and Quantitative PCR (qPCR). 
The RT-PCR is a PCR technique that uses RNA as the 
original template. It uses reverse transcriptase for DNA 
synthesis from the RNA template followed by PCR. Real-
time PCR can observe the amplification product in real-
time, during the PCR process by using a fluorescent label 
that binds to the final PCR product (Higuchi et al., 1993; 
Deepak et al., 2007). The qPCR can be used to quantify 
nucleic acids at a specific time. For gene expression 
studies, RT-PCR, real-time PCR, and qPCR are combined 
into one process called RT- qPCR or rRT-PCR. This 
process includes DNA synthesis from an RNA template 
using reverse transcriptase, followed by PCR, detection, 
and quantification. This method is used for the diagnosis 
of the Coronavirus disease or COVID-19 since SARS-
CoV-2 is an RNA virus. This test is accurate and sensitive 
enough for detecting SARS-CoV-2 in samples (Long et al., 
2020; Tahamtan & Ardebili, 2020). 
 
RT-PCR KITS 
Real-time PCR is the most sensitive method to detect the 
presence of the virus that causes COVID-19. Real-time 
PCR can detect viruses with a detection limit (analytical 
sensitivity) of 1000 copies/mL, this analytical sensitivity 
depends on sample volume, elution volume, and RNA 
extraction methods, and other factors (Tahamtan & 
Ardebili, 2020). Many RT-PCR kits can be used as 
diagnostic tools for COVID-19. van Kasteren et al. (2020) 
compared the performance of seven RT-PCR kits. The 
kits that were assessed are shown in Table I. 
Table I. RT-PCR kits for COVID-19 diagnosis (van Kasteren 
et al., 2020) 
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Altona 
Diagnostics 
Germany −20°Cc RUOa Eb, S 
BGI China −20°C CE-
IVD 
ORF1ab 
CerTest 
Biotec 
Spain Room 
Temp.  
CE-
IVD 
ORF1ab, 
N 
KH Medical Korea  −20°C CE-
IVD 
RdRp, S 
PrimerDesign  England  −20°C CE-
IVD 
RdRp 
 
R-Biopharm 
AG 
Germany  −20°C RUOd E 
Seegene Korea  −20°C CE-
IVD 
N, Eb 
E: Envelope protein of SARS Cov-2 
CE-IVD: European conformity label-in Vitro diagnostics 
RdRp: RNA dependent RNA polymerase of SARS Cov-2 
N: Nucleocapsid protein of SARS-Cov-2 
ORF1ab: Open Reading Frame 1a and b of SARS Cov-2 
RUO: Research Use Only 
S: Spike protein of SARS Cov-2 
aAccording to the manufacturer's website the kit is RUO, the FindDx 
website states CE-IVD certification for this kit. 
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bThese E-gene assays are specific for bat (-related) beta coronaviruses. 
They detect both SARS-CoV-1 and -2. 
cShipment is performed at room temperature. 
dAccording to the manufacturer, CE-IVD certification will be applied 
shortly. 
 
All RT-PCR kits performed splendid results with PCR 
efficiency ≥96%. All RT-PCR were able to identify 
positively 10 out of 13 selected clinical samples with 
various concentrations, with the highest concentrations 
of SARS-CoV-2 RNA with Ct less than 34.5 in an in-house 
E-gene PCR. None of the assays showed cross-reactivity 
with a confirmed non-coronavirus respiratory viral 
infection. When performing diagnostics in a low viral 
loads condition such as in mild or no symptoms or 
patients during the later stage of infection or health-care 
workers (Zou et al., 2020), RT-PCR kits from R-Biopharm 
AG, BGI, KH Medical, and Seegene had the best 
performance in identification of the clinical samples. All 
the RT-PCR kits assessed in the study may be used for 
routine diagnostics of COVID-19 in patients by 
experienced molecular diagnostic laboratories. 
 
RT-PCR TEST SAMPLES 
In general, most patients only develop mild (40%) or 
moderate (40%) disease, 15% develop in the severe 
condition that requires oxygen support, and 5% have a 
critical disease with complications such as respiratory 
failure, acute respiratory distress syndrome (ARDS), 
sepsis and septic shock, thromboembolism, and/or 
multiorgan failure, including acute kidney injury and 
cardiac injury (World Health Organization, 2020c). RT-
PCR test samples for initial diagnosis come from the 
upper respiratory tract (URT) in the form of 
nasopharyngeal (NP) and oropharyngeal (OP) swabs, 
nasopharyngeal wash/nasopharyngeal aspirate, nasal 
swab, or nasal mid-turbinate swab. If the URT specimen 
shows a negative result, then the specimen is taken from 
the lower respiratory tract (LRT) consisting of sputum, 
aspirate, or lavage (Center for Disease Control and 
Prevention, 2020a; World Health Organization, 2020b). In 
other considerations, stools can be used as specimens for 
RT-PCR samples (World Health Organization, 2020b). 
Some patients show negative swabs, but viral RNA can 
be detected in the stool (Hindson, 2020; Lo et al., 2020; 
Wölfel et al., 2020). The specimen is collected as soon as 
possible in the initial onset (Center for Disease Control 
and Prevention, 2020b). Research showed that the viral 
loads in throat swab and sputum peaked in 5-6 days after 
symptom onset (Pan et al., 2020). Another research 
indicated that viral load was higher in the nose (NP and 
OP swabs) than in the throat (Zou et al., 2020). 
The use of NP swabs as a specimen is preferred over OP 
swabs due to higher detection rates. This is consistent 
with research that demonstrates early viral development 
in the nasal/NP (Wang et al., 2020). Sampling techniques 
through swabs must be performed at the right anatomy 
and time so that negative-false can be avoided. Besides, 
only synthetic fiber swabs with plastic or wire shafts are 
used (Center for Disease Control and Prevention, 2020b). 
In NP swabs, mini tip swabs are inserted into the nose 
parallel to the palate until they reach the tip, namely the 
nasopharynx. Gently rub and roll the swab and wait a 
few seconds to absorb the secretion. Then slowly remove 
the swab while rotating it. The technique for collecting 
specimens in the form of an NP swab is illustrated in 
Figure 2. The OP swab is done by inserting the swab into 
the posterior pharynx and tonsillary areas (Center for 
Disease Control and Prevention, 2020b; World Health 
Organization, 2020b). Each swab is put into a sterile 
container containing 2-3 mL viral transport medium 
(VTM), Amies transport medium, or sterile saline. The 
specimens for LRT are placed in dry and sterile 
containers (Center for Disease Control and Prevention, 
2020b). 
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Figure 2. Nasopharyngeal Swab (Center for Disease Control 
and Prevention, 2020b) 
 
Collected specimens are stored at 2-8°C for up to 72 
hours. If a delay in testing or shipping is expected, store 
specimens at -70°C or below (Center for Disease Control 
and Prevention, 2020b). Complete information about 
specimen collection and storage is in Table II. 
Table II. Specimen collection and storage (Center for Disease 
Control and Prevention, 2020b; World Health 
Organization, 2020a) 
Specimen type 
Collection 
materials 
Storage 
temperature 
until testing 
in-country 
laboratory 
The 
recommended 
temperature 
for shipment 
according to 
expected 
shipment time 
Nasopharyngeal 
and 
oropharyngeal 
swab 
Dacron or 
polyester 
flocked 
swabs* 
2-8°C 
2-8°C if ≤ 12 
days 
–70°C (dry ice) 
if > 12 days 
Bronchoalveolar 
lavage 
Sterile 
container* 
2-8°C 
2-8°C if ≤ 2 days 
–70°C (dry ice) 
if > 2 days 
(Endo)tracheal 
aspirate, 
nasopharyngeal 
or nasal 
wash/aspirate 
Sterile 
container* 
2-8°C 
2-8°C if ≤ 2 days 
–70°C (dry ice) 
if > 2 days 
Sputum 
Sterile 
container 
2-8°C 
2-8°C if ≤ 2 days 
–70°C (dry ice) 
if > 2 days 
Stool 
Stool 
container 
2-8°C 
2-8°C if ≤ 5 days 
–70°C (dry ice) 
if > 5 days 
*For transport of samples for viral detection, use viral transport medium 
(VTM) containing antifungal and antibiotic supplements. Avoid repeated 
freezing and thawing of specimens. If VTM is not available sterile saline 
may be used instead (in which case, duration of sample storage at 2-8°C 
may be different from what is indicated above). 
 
Low viral load (World Health Organization, 2020b) is one 
of the things that can negatively impact the results of the 
RT-PCR analysis. It is recommended that NP be collected 
twice from both sides of the nostrils or that OP and NP be 
combined in one VTM to maximize test sensitivity and 
limit the use of test resources (Center for Disease Control 
and Prevention, 2020b). The second factor is that the 
specimen was collected late or very early in the infection. 
Hence, it is very important to take specimens at the right 
time. The third is that the specimen was not properly 
handled and shipped. Another factor is the technical 
reasons inherent in the test, e.g. virus mutation or 
inhibition of PCR (World Health Organization, 2020b). 
 
STEPS IN INVESTIGATION OF COVID-19 
SPECIMEN SAMPLES 
In Indonesia, The Ministry of Health has issued a direct 
procedure for handling the COVID-19 sample at the 
National Board of Health Research and Development. 
Specimen investigations have followed WHO standards 
and were carried out at the Biosafety Level 2 (BSL-2) 
Laboratorium. The investigation procedure is divided 
into three stages, consisting of acceptance, examination, 
and reporting.  At the acceptance stage, specimens are 
taken from patients at the referral hospital and then sent 
to the National Board of Health Research and 
Development. To ensure further accuracy, not only one, 
but three specimens should be obtained from one patient. 
A swab sample from a COVID-19 patient is taken by a 
sampling officer with a Personal Protective Equipment 
(PPE) to be mixed with the VTM (Ministry of Health of 
the Republic of Indonesia, 2020a). 
The VTM can be used to collect specimens from the 
throat and nasal swabs from human patients. This 
solution can be prepared locally based on the WHO 
recommendation. The VTM contains infusion broth, 
bovine albumin fraction V, gentamicin sulfate, 
amphotericin B, and sterilized distilled water. 
Commercial VTM is also available such as COPAN 
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Universal Transport Medium and Eagle Minimum 
Essential Medium (E-MEM) (World Health 
Organization, 2006). 
Continuing to the examination stage, at this stage, the 
specimens received by the National Board of Health 
Research and Development are extracted for their RNA 
(Ribonucleic Acid) or viral genetic material. After the 
RNA is obtained, it is then used as a template for Reverse 
Transcriptase-Quantitative Polymerase Chain Reaction 
(RT-qPCR) to detect the presence of specific SARS CoV2 
genes. COVID-19 diagnoses of patients are based on the 
RT-PCR test results (Ministry of Health of the Republic of 
Indonesia, 2020b). 
In the RT-PCR process, there are negative and positive 
controls. In the negative control, the amplification of viral 
genes must not be found while in the positive control 
there must be an amplification of viral genes that are 
marked by curves. If the RT-PCR negative control is 
found to be positive, then the PCR process must be 
repeated (Bustin & Nolan, 2004). The final stage is the 
reporting, there was indeed a special channel that needed 
to be done first to report or confirm the results. After 
interpretation of the results by RT-PCR experts, these 
results were sent to doctors who will carry out the next 
stage of verification and validation to report to the 
hospital and the health service (Espy et al., 2006). 
 
FALSE POSITIVE RESULTS IN THE RT-
PCR TEST 
The false-positive result of the RT-PCR test means that 
the test is positive even if no virus is present in the sample 
tested. False-positive results of the RT PCR diagnostic 
tests are very unlikely. Positive results depend on the 
sequences of the primers and probes used, and possible 
cross-reactions with non-target sequences have usually 
already been ruled out during the design phase (Bustin 
& Nolan, 2020). 
For example, the SARS-CoV-2 rRT-PCR Diagnostic 
Panel primer and probe sequences were tested for 
homology with human genome sequences, other 
coronaviruses, and human microflora to prevent 
potential false-positive results (Center for Disease 
Control and Prevention, 2020a). No homology was 
found with the human genome and microflora 
sequences, but one of the primers or probes had 
homology with SARS-CoV and Bat SARS-like 
coronavirus genome. Since homologies with these 
coronavirus genomes were not present for the whole set 
of primers and the RT-PCR reaction probe, a false 
positive outcome would be unlikely (Corman et al., 2020). 
For a false-positive result to happen, the sample could 
have been contaminated with the virus (Tahamtan & 
Ardebili, 2020). Contamination from equipment and 
reagent could be a source of false-positive results. 
Usually, this type of potential false positive would be 
detected by the use of negative control reactions. If the 
negative control reaction was positive, the test result 
would not have been valid and the test had to be 
repeated. This occurred in a test facility in Yala, Southern 
Thailand, where the negative controls of 40 specimens 
showed positive results. When the problematic 
specimens were sent to two other laboratories for 
analysis, the results were consistently negative. Machine 
error was suspected to be the cause of false-positive 
results (Thai Public Broadcasting Service World, 2020). 
 
FALSE NEGATIVE RESULTS IN THE RT-
PCR TEST 
False-negative results from RT-PCR are much more 
common compared to false-positive results and have 
more serious consequences in the epidemiological 
management of the disease (Kalifarhood et al., 2020). 
Every RT PCR kits have a limit of detection, ranging from 
200-1000 copies/mL, and this is the limit of detection 
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under controlled laboratory conditions. Under real-life 
conditions, the limit of detection could become higher. 
Therefore, a low viral load could cause false-negative 
results. Mistakes during specimen collection, storage, 
and transportation could result in false-negative results 
(Jagodzinski et al., 2020). 
Variations in the target sequence could cause false-
negative results. The SARS-CoV-2 has evolved into three 
central variants (Forster et al., 2020). Even though the 
design of primers and probes has taken into account 
variations in the SARS-CoV-2 genome sequences, new 
mutations could occur in the target sites. 
The viral load would fluctuate during disease 
progression. From 72 nasal swabs and 72 throat swabs 
obtained from 18 patients in Zhuhai, Guangdong, China, 
the Ct value from 0 to 21 days after symptom onset 
fluctuated. A Ct value of 40 was considered to be 
negative and several patients Ct values decreased 
(positive results) after a previous Ct value of 40 (negative 
results), and some patients had inconsistent results (one 
positive and one negative) from nasal and throat swabs 
taken on the same day (Zou et al., 2020). Negative test 
results that later became positive were also observed in 
other longitudinal studies. According to Kucirka et al. 
(2020), from samples collected from the upper respiratory 
tracts, no virus could be detected with RT-PCR on the 
day of infection. On the day of symptom onset, the 
median false-negative rate was 38%, and the lowest false-
negative rate of 20% was obtained from samples 
collected three days after symptom onset. Then the false-
negative rate would increase again, reaching 66% at 16 
days after symptoms onset. 
 
CONCLUSION 
COVID-19 is caused by SARS-CoV-2, an enveloped 
RNA virus with a large genome (29.9 kb) closely related 
to human SARS-CoV and bat SARS-CoV. The S protein 
on the surface of SARS-CoV-2 binds to the ACE2 receptor 
of the host and promotes entry of the virus into the cell 
target. ACE2 receptors are present in cells of the arteries, 
veins, smooth muscles, small intestine, alveoli of the 
lungs, hair follicles, cardiac myofibroblasts, skin, brain, 
and kidney, thus SARS-CoV-2 could potentially infect 
these tissues. The gold standard for detection or SARS-
CoV-2 is by rRT-PCR and kits for SARS-CoV-2 detection 
are available commercially. Proper sampling site, 
sampling method, the timing of sampling, treatment, and 
handling of specimens during shipping and storage are 
all important in obtaining correct test results. Ongoing 
research is needed to select a better sampling site, timing, 
and treatment of samples to minimize false results which 
have serious consequences for the management of the 
disease. 
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